

ASX ANNOUNCEMENT



1 October 2025

Convertible Note Facility

CONNEQT Health Limited (ASX: CQT) (“**CONNEQT**” or “the **Company**”) is pleased to announce it has entered into a Convertible Note Subscription Agreement with C2 Ventures Pty Ltd (“**C2V**”, owned by Directors, Niall Cairns and Craig Cooper) (the “**Agreement**”).

The total subscription proceeds received to date in the form of a loan advance (A\$2 million), represent a meaningful capital injection that provides the Company with additional flexibility to continue executing its business and market development plans. The support from cornerstone investor C2V, ensures that CONNEQT can maintain momentum in its commercialisation activities.

Key Terms of the Convertible Note Facility

Term	Details
Funding Amount	A\$2,000,000
Subscriber	C2 Ventures Pty Ltd (owned by Directors, Niall Cairns and Craig Cooper)
Instrument	Unsecured loan to be applied to a subscription for Convertible Notes upon shareholder approval
Interest Rate	10% per annum (minimum interest period: 6 months)
Commitment Fee	2% of the facility amount
Ranking	Notes are unsecured debt obligations ranking equally without preference or priority among themselves
Denomination	Each Note is issued in an amount equal to its principal face value (\$1.00 per Note)
Conversion Price	Lower of \$0.04 (last equity raise) or 10% discount to the issue price of the next qualifying capital raise (being A\$5 million or more)
Conversion election	By the Company following a qualifying capital raise By the Noteholder at any time after the first 3 months from issue and up to maturity
Maturity Date	30 June 2026 (repaid in cash if not converted earlier)
Security	Unsecured
Use of Funds	General working capital and corporate purposes

C O N N E Q T
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Barangaroo 2000
Sydney, Australia

+61 2 9874 8761

For personal use only

The conversion of the existing unsecured loan into Convertible Notes, and the issue of shares upon any future conversion of those Notes, is subject to shareholder approval. The notice of 2025 AGM containing full details of the Facility and proposed resolutions will be provided to shareholders in due course.

Contingent Adjustment if Shareholder Approval Is Not Obtained

If shareholder approval is not obtained by 30 December 2025, and subject to conditions being met, a contingent cash adjustment may be payable to C2V representing foregone share price gains had shareholder approval been obtained. This would only apply if the Company's share price exceeded \$0.04 at the relevant time (being either the date a resolution is put to shareholders and is not passed, or the deadline is reached with no resolution being put to shareholders). No adjustments are payable if the share price is \$0.04 or below. Further, if shareholder approval is not obtained for the conversion of the existing unsecured loan into Convertible Notes, then C2V will be able to call for repayment of the loan on 30 days' notice.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").